Navigation Links
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Date:5/20/2008

in estimates that PEG-PAL could be a potential treatment option for a significant portion of the PKU population.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate PEG-PAL, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials re
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Announces FDA Approval for Kuvan
2. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
8. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
11. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Conn. , July 29, 2014 Numotion,s Board ... Mike Swinford will be the company,s new Chief ... highly successful 22-year career at GE where he worked primarily ... in annual revenue to over $5 billion. His most recent ... Services. "I am thrilled to join Numotion," ...
(Date:7/29/2014)... July 29, 2014 McGraw-Hill Education Professional, a ... science, technical, and medical communities, has announced the launch ... mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all iOS ... able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... DIEGO , July 29, 2014  Neurocrine Biosciences, ... the Company will report its second quarter 2014 financial ... 6, 2014.  Neurocrine will then host a live conference ... provide a Company update Thursday morning, August 7, 2014 ... Participants can access the live conference call ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... on the short arm of chromosome 6 (6p21.3), is a ... region is the human equivalent of the Major Histocompatibility Complex ... serve as the backbone of antigen presentation. The Class ... T-cells, are expressed by genes located in the HLA-A, -B ...
... the level of blood oxygenation can be an ... levels in the clinical setting is often desirable. ... sophisticated technology into easily used point-of-care devices, recent ... hemoglobin values., ,HemoCue, Inc., Lake Forest, Calif., says ...
Cached Medicine Technology:The Past, Present and Future of HLA Typing 2The Past, Present and Future of HLA Typing 3Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3
(Date:7/29/2014)... The National Congress of American Indians (NCAI) ... Washington NFL team owner Dan Snyder asking him to disavow ... slur is emanating from “well-intentioned elites” who are “not Native ... to respond. , The Change the Mascot campaign ... which was first reported by Erik Brady of USA ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The ... Pharmaceutical, Cosmetics), Type (Rotary, Volumetric, Aseptic, Net Weight), ... & Geography - Global Trend & Forecast to ... it into food, beverage, pharmaceutical, and cosmetic segments ... of each of these segments, in terms of ...
(Date:7/29/2014)... 29, 2014 Outsourced coding and ... in the number of hospitals contracting for external ... deadline, according to the recently published Black Book™ ... found in the reports “Top Ranked Clinical Documentation ... outsource Clinical documentation audit, review and programming. By ...
(Date:7/29/2014)... 29, 2014 July 29, 2014 - ... at the source? That’s the big public health question ... drug abuse risk program developed by Principled Strategies ... worldwide to be part of The Hive ... Francisco, CA. The Hive is a community of exceptional ...
(Date:7/29/2014)... $3.4 million this year to support innovative research ... diseases that affect more than 233,000 Canadians. ... projects across Canada. This diverse research will explore ... our understanding (and potential treatment) of symptoms and ... of life. , Crohn,s and Colitis Canada ...
Breaking Medicine News(10 mins):Health News:Native American Groups Urge Washington Team Owner Dan Snyder to Stop Claiming Name Change Issue Driven by "Elites" Who Are Not People of Color 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 3Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 4Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 3Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 2Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 3Health News:Prestigious Crohn's and Colitis Canada grants fund promising Canadian research 2
... 23 As the health insurance market increasingly becomes ... serve customers with face-to-face assistance at the company,s first ... Mount Pleasant, S.C.Located at 615 Johnnie Dodds Blvd., Suite ... the 1,800 square foot SC BlueStore(SM) will ...
... the first new President to develop a comprehensive cancer ... disturbingly no reference is made to prevention, and the ... and coordinates the responsibilities of four federal agencies: ... trials; the Centers for Disease Control and Prevention ...
... an effort to keep patient care a priority, some ... to participate in an unfair labor practice strike at ... 6 a.m. on Friday January 23.The nurses, members of ... Health Care Employees AFSCME, AFL-CIO, have been working without ...
... adjustment helps Social Security beneficiaries; Allsup outlines other benefits of SSDI ... ... With the arrival of 2009, Social Security disability recipients are seeing ... to Allsup , which represents tens of thousands of people ...
... rates reach the highest levels in 16 years, a ... laid-off workersonly 9 percenttook up coverage under the Consolidated ... who also lose their health insurance would need substantial ... health insurance premiums, for their premium contributions to remain ...
... 22 On the day that millions of Americans ... Court,s Roe v. Wade decision ... 50 million lives, President Barack Obama was widely expected ... Policy," which prohibits taxpayer funds from going to foreign ...
Cached Medicine News:Health News:S.C. BlueCross Hosts Grand Opening of Its First Health Insurance Retail Store 2Health News:The Obama Cancer Plan Should Prioritize Prevention, Says Cancer Prevention Coalition 2Health News:The Obama Cancer Plan Should Prioritize Prevention, Says Cancer Prevention Coalition 3Health News:The Obama Cancer Plan Should Prioritize Prevention, Says Cancer Prevention Coalition 4Health News:The Obama Cancer Plan Should Prioritize Prevention, Says Cancer Prevention Coalition 5Health News:Social Security Disability Recipients See Benefits Increase In New Year, But May Not in 2010 2Health News:Social Security Disability Recipients See Benefits Increase In New Year, But May Not in 2010 3Health News:Social Security Disability Recipients See Benefits Increase In New Year, But May Not in 2010 4Health News:Only about one of ten unemployed workers obtain COBRA coverage 2Health News:President Obama Gives the Unborn at Least a 24 Hour Reprieve, Postpones $441 Million Bailout of International Abortions, Says Family Research Council 2
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... Indirect Fluorescence Assay (IFA) for IgG ... for the qualitative and semi-quantitative detection ... in human serum. Detection of ANA ... an aid in the diagnosis of ...
... Assay measures changes in platelet function ... (Plavix). It uses a specific activator ... inhibits. The assay has not been ... assay is available for Research Use ...
The Wide Angle Twin Mag NP combines the performance of two instruments to deliver unequalled power and versatility into the hands of eye care professionals....
Medicine Products: